Abstract 1752P
Background
In France, new treatments’ benefit is evaluated by the Haute Autorité de Santé (HAS) to inform on reimbursement and pricing, but they are rarely evaluated afterwards. Although immunotherapies (ITs) considerably improved patients’ survival, few data are available on their clinical benefit at the population-treated level. The objective of this study was to retrospectively quantify the clinical benefit of ITs compared to previous standard of care (SoC) in France from 2014 to 2021.
Methods
Analysis covers all ITs marketed in early access and/or reimbursed in France between 2014 and 2021, regardless of indication, with a cost-effectiveness (CE) model validated by HAS. For year between 2014 and 2021, the number of patients having initiated an IT, per drug and per indication, was retrieved from the French Hospital Reimbursement database. The clinical benefit was expressed as the number of deaths prevented (DP), life years gained (LYG) and quality-adjusted life years (QALYs) of ITs versus their comparators until 2021. DP and LYG were calculated thanks to extrapolated overall survival curves from randomized clinical trials, validated by the HAS. The number of additional QALYs was calculated using utility scores from the HAS CE opinion. Sensitivity analyses were performed according to the population size, survival, utility values and the period of availability.
Results
From 2014 to 2021, 5 ITs (atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab) were available in monotherapy or in combination in France corresponding to 8 tumor types and 21 indications. Overall, 132,924 patients initiated an IT, mainly in non-small cell lung cancer (66.5%) and melanoma (12.3%). By Dec 31st of 2021, 16,173 [13,803 – 17,141] deaths were prevented compared to previous SoC, representing 12.2% of patients initiating an IT. Compared to previous treatments, ITs allowed 37,318 [33,583 – 41,053] LYG and 27,710 [23,785 – 30,451] QALYs. Nivolumab contributed in 64.6% of LYG and 63.1% of QALYs. Early access of ITs participated in 14.7% of DP, 6.1% LYG and 6.0% QALYs.
Conclusions
Immunotherapies allowed significant clinical benefits for French cancer population in term of DP, LYG and QALYs. This type of analysis should be replicate in other countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
F. Cotté, A. Gaudin, V. Grumberg: Financial Interests, Personal, Full or part-time Employment: BMS. E. Giroux-Leprieur: Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, MSD, Novartis, Roche, Sanofi, Boehringer Ingelheim, AstraZeneca, Takeda, Jansen, Pfizer. C. Lebbe: Financial Interests, Institutional, Advisory Board: Amgen, Bristol Myers Squib, Merck, MSD, Novartis, Pierre Fabre, Roche, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1746P - Unintended consequences: Working time directives and oncology staff implications
Presenter: Simon Barry
Session: Poster session 23
1747P - The need for a better discussion between doctors and patients with regards to fertility preservation and vaginal rehab after anti cervical cancer treatments
Presenter: Bar Levy
Session: Poster session 23
1748P - Tackling childhood obesity epidemic on southern Europe through soft drink advertisement policies: Should oncology societies have a say?
Presenter: Konstantinos Kamposioras
Session: Poster session 23
1749P - Prevention of modifiable cancer risks in informal family caregivers of cancer patients: Implementation and evaluation of a personalised primary prevention intervention (PREV-AIDANT)
Presenter: Beatrice Fervers
Session: Poster session 23
1751P - Re-ranking cancer mortality using years of life lost
Presenter: Cecilia Radkiewicz
Session: Poster session 23
1753P - Universal DPYD genotyping in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy
Presenter: Claudia Cardone
Session: Poster session 23
1754P - Towards a next-generation sequencing/comprehensive genomic profiling value framework: Systematic review for identifying new domains and adapting a diagnostic test value framework in Europe
Presenter: Federico Augustovski
Session: Poster session 23
1755P - Carbohydrate quality index and incidence of obesity-related cancers: The Seguimiento Universidad de Navarra (SUN) project
Presenter: Maria Olmedo López-frías
Session: Poster session 23
1756P - Vizcan: A Swedish population-based study to address cancer outcomes using an interactive platform
Presenter: Anders Berglund
Session: Poster session 23